Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

  • There is currently no data for AGL

Rule 8.3- Angle PLC

5 Sep 2008 13:23

RNS Number : 8594C
Kaupthing Bank hf
05 September 2008
 



  FORM 8.3

DEALINGS BY PERSONS WITH INTERESTS IN SECURITIES REPRESENTING 1% OR MORE 

(Rule 8.3 of the Takeover Code)

1. KEY INFORMATION

Name of person dealing  (Note 1)

Kaupthing Bank hf

 

Company dealt in

Angle Plc

 

Class of relevant security to which the dealings being disclosed relate (Note 2)

 

Ordinary Shares

Date of dealing

4 September 2008

2. INTERESTS, SHORT POSITIONS AND RIGHTS TO SUBSCRIBE

(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

Long

Short

Number (%)

Number (%)

(1) Relevant securities 

5,929   (0.02%)

(2) Derivatives (other than options)

1,017,125 (3.75 %)

1,017,125  (3.75%)

(3) Options and agreements to purchase/sell

Total

1,023,054 (3.77%)

1,017,125 (3.75%)

(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

Class of relevant security:

Long

Short

Number (%)

Number (%)

(1) Relevant securities 

(2) Derivatives (other than options)

(3) Options and agreements to purchase/sell

Total

(c) Rights to subscribe (Note 3)

Class of relevant security:

Details

3. DEALINGS (Note 4)

(a) Purchases and sales

Purchase/sale

Number of securities

Price per unit (Note 5)

Sell

6,598

22.43p

 (b) Derivatives transactions (other than options)

Product name, 

e.g. CFD

Long/short (Note 6)

Number of securities (Note 7)

Price per unit (Note 5)

(c) Options transactions in respect of existing securities

(i) Writing, selling, purchasing or varying

Product name,

e.g. call option

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 7)

Exercise

price 

Type, e.g. American, European etc.

Expiry 

date

Option money

paid/received per unit (Note 5) 

(ii) Exercising

Product name, e.g. call option

Number of securities 

Exercise price per unit (Note 5)

(d) Other dealings (including new securities) (Note 4)

Nature of transaction (Note 8)

Details

Price per unit (if applicable) (Note 5)

4. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

No voting rights on CFD holdings

Is a Supplemental Form 8 attached? (Note 9) NO

Date of disclosure

5 September 2008

 

Contact name

Kavita Thaker

 

Telephone number

0203 205 6621

 

If a connected EFM, name of offeree/offeror with which connected

If a connected EFM, state nature of connection (Note 10)

Notes

The Notes on Form 8.3 can be viewed on the Takeover Panel's website at www.thetakeoverpanel.org.uk

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RETBDGDCDDGGGIU
Date   Source Headline
26th Mar 20184:35 pmRNSPrice Monitoring Extension
26th Mar 20187:00 amRNSResearch Update
6th Feb 20187:00 amRNSANGLE plc: RESEARCH GRANT FROM ABBOTT
31st Jan 20187:00 amRNSInterim Results
16th Jan 20187:00 amRNSWEBINAR:USING PARSORTIX TO TEST DRUGS ON LIVE CTCS
10th Jan 201810:16 amRNSNotice of Results
8th Jan 20187:00 amRNSANGLE plc:Prostate cancer ARV7 treatment biomarker
27th Dec 201711:49 amRNSHolding(s) in Company
12th Dec 20177:00 amRNSTransfer of Lock-in Shares
8th Dec 20177:00 amRNSPARSORTIX POTENTIAL IN METASTATIC BREAST CANCER
28th Nov 20177:00 amRNSParsortix enables CTC molecular characterisation
23rd Nov 20177:00 amRNSPHILIPS COLLABORATION IN BREAST AND RECTAL CANCER
17th Nov 20174:06 pmRNSHolding(s) in Company
16th Nov 20178:23 amRNSTotal Voting Rights and Covington Subscription
6th Nov 20177:00 amRNSHolding(s) in Company
6th Nov 20177:00 amRNSHolding(s) in Company
6th Nov 20177:00 amRNSHolding(s) in Company
2nd Nov 201710:04 amRNSHolding(s) in Company
1st Nov 20178:12 amRNSANGLE: Completion of Fundraising and Acquisition
31st Oct 20172:18 pmRNSResult of AGM
30th Oct 201710:31 amRNSResult of General Meeting
26th Oct 20178:10 amRNSTotal Voting Rights
23rd Oct 20177:00 amRNSParsortix harvests cancer cells from bone marrow
20th Oct 20173:05 pmRNSNotice of AGM
17th Oct 20177:00 amRNSANGLE: 7th Peer Reviewed Publication On Parsortix
12th Oct 20177:00 amRNSProposed further subscription for £2.8 million
9th Oct 20177:02 amRNSCTCs harvested with Parsortix grown in laboratory
9th Oct 20177:01 amRNSPotential new analytical protocol using Parsortix
9th Oct 20177:00 amRNSParsortix Showcased at CTC Conference
5th Oct 201711:46 amRNSResults of Fundraising
5th Oct 20177:00 amRNSAcquisition and Fundraising
13th Sep 20175:36 pmRNSHolding(s) in Company
13th Sep 20177:00 amRNSExclusive worldwide option over megakaryocyte IP
11th Sep 20177:00 amRNSCo-Marketing Partnership with QIAGEN
5th Sep 20177:00 amRNSChange of Adviser
4th Sep 20177:00 amRNSNew Research with Parsortix
27th Jul 20177:00 amRNSPreliminary Results
20th Jul 20171:00 pmRNSPreclinical Study Presented At Tumor Boston Summit
6th Jul 201710:05 amRNSNotice of Results
4th Jul 20177:00 amRNSSuccessful Headline Data in Ovarian Cancer Studies
15th Jun 20177:00 amRNSParsortix breakthrough in prostate cancer
5th Jun 20177:00 amRNSSuccess with Parsortix in Colorectal Cancer
3rd May 20177:00 amRNSBusiness Update
4th Apr 20177:00 amRNSHolding(s) in Company
3rd Apr 20177:00 amRNSParsortix enables analysis in head and neck cancer
30th Mar 20177:00 amRNSProstate Cancer Update
14th Feb 201711:39 amEQSEdison issues outlook on Angle
13th Feb 20177:00 amRNSSelected for European Cancer ID Programme
26th Jan 20177:01 amRNSInterim Evaluation of Ovarian Cancer Study
26th Jan 20177:00 amRNSInterim Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.